Skip to content
PICO Portalanswers from OpenAlex

Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease

PaperCitations, authors & open-access status

Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease is a paper indexed in PICO Portal from OpenAlex.

How many citations does Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease have?

PICO Portalcitation count

Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease has 1,654 citations in the OpenAlex counts PICO Portal stores.

When was Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease published?

PICO Portalyear

Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease has 2014 year in the PICO Portal index.

What is the open-access status of Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease?

PICO Portaloa status

Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease has bronze oa status in the PICO Portal index.

What is the DOI of Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease?

PICO Portaldoi

The DOI for Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease is on the source record.

What is the PMID of Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease?

PICO Portalpmid

The PMID for Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease is on the source record.

What is the OpenAlex record for Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease?

PICO Portalopenalex

The OpenAlex for Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease is on the source record.

Related on PICO Portal

470M+ articles · 14-day free trial